Tumor suppressor p53 is reported to be an attractive immunotherapy target because it is
mutated in approximately half of human cancers, resulting in inactivation and often an …

Owing to their central role in the initiation and regulation of antitumor immunity, dendritic
cells (DCs) have been widely tested for use in cancer immunotherapy. Despite several …

Dendritic cell (DC)–based immunotherapy can trigger effective immune responses against
cancer in human patients. Although accompanied by little toxicity, further improvements are …

Impressive advances have been seen in cancer immunotherapy during the last years.
Although breast cancer (BC) has been long considered as non-immunogenic …

Recently, the US FDA approved sipuleucel-T, which is composed of autologous DCs
stimulated with a recombinant fusion protein of prostatic acid phosphatase (PAP) and …

Tumor-associated antigens (TAAs) have been identified in many malignant tumors. Within
these TAAs are peptide sequences that bind major histocompatibility complex (MHC) class I …

The current “gold standard” for generation of dendritic cell (DC) used in DC-based cancer
vaccine studies is maturation of monocyte-derived DCs with tumor necrosis factor-α (TNF …

This article reviews the principal attempts of immune-modulation or immune therapy in
metastatic breast cancer. It considers their rationale and reports on results from the relevant …

Although immunogenicity is typically associated with renal cell carcinomas and melanoma,
there are several compelling reasons why immune-based therapies should be explored in …

ABSTRACT p53 was reported to be an attractive immunotherapy target because it is
mutated in approximately half of human cancers, resulting in its inactivation and often …